Priothera’s Mocravimod improves survival for patients with hematological malignancies
Priothera, a biotechnology company developing its S1P receptor modulator compound Mocravimod, has announced that positive…
November 14, 2022 - 2 minutes
graft versus host disease
Hope for children with chronic graft versus host disease as Johnson & Johnson drug approved
A treatment for chronic graft versus host disease in children aged one year and older…
August 25, 2022 - 3 minutes
Mass Layoffs as Dutch Biotech Cancels Phase III Cell Therapy Trial
The Dutch company Kiadis Pharma has discontinued the development of a cell therapy in blood…
November 13, 2019 - 2 minutes
Series B Funding Helps Dutch Biotech Fight Graft Versus Host Disease
Xenikos has raised $30M (€25M) in Series B funding to conduct Phase III trials for…
May 15, 2018 - 2 minutes
Dutch Biotech Gets Special Designation for Reduced Risk Blood Cancer Treatment
The FDA has backed Kiadis Pharma's lead blood cancer product by granting it the Regenerative Medicine…
September 20, 2017 - 2 minutes
Meet the New CEO of the Dutch Biotech Making a Cure for Blood Cancer
Arthur Lahr, CEO of Kiadis Pharma, explains the promising cell therapy the company is developing…
May 22, 2017 - 7 minutes
New Research could Save Patients from Graft-Versus-Host Disease
A new study published in the journal Science Translational Medicine identifies a new treatment strategy…
April 25, 2017 - 3 minutes
This Dutch Company is Upgrading ADCs for Immunotherapy
T-Guard is CEO and co-founder Ypke van Oosterhout’s life work. He told us about the…
March 13, 2017 - 7 minutes
Curing Cancer with Safer Transplants: UK Approval to start Clinical Trials
Kiadis Pharma has received approval to test in the UK an immune therapy to address…
December 15, 2016 - 2 minutes
How is European Immuno-Oncology fighting Blood Cancer?
From leukemia to multiple myeloma, biotech is working hard to cure blood cancer. This year's…
December 6, 2016 - 4 minutes
Will the Leading Italian Biotech soon have its First Cell therapy on the Market?
MolMed has received conditional market approval for Zalmoxis, an ex vivo genetically engineered cell therapy that stops immune…
June 28, 2016 - 2 minutes
